<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006011</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0184</org_study_id>
    <secondary_id>NCI-2012-02350</secondary_id>
    <secondary_id>ECOG-G0184</secondary_id>
    <secondary_id>RTOG-EN0130</secondary_id>
    <secondary_id>CDR0000068020</secondary_id>
    <secondary_id>GOG-0184</secondary_id>
    <secondary_id>GOG-0184</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00006011</nct_id>
  </id_info>
  <brief_title>Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer</brief_title>
  <official_title>A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      Randomized phase III trial to compare the effectiveness of two combination chemotherapy
      regimens plus radiation therapy in treating patients who have stage III or stage IV
      endometrial cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs
      used in chemotherapy use different ways to stop tumor cells from dividing so they stop
      growing or die. Combining more than one chemotherapy drug with radiation therapy may kill
      more tumor cells. It is not yet known which combination chemotherapy regimen plus radiation
      therapy is more effective for endometrial cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Compare survival and progression-free survival in patients with stage III endometrial
      carcinoma treated with tumor volume-directed pelvic radiotherapy with or without paraaortic
      radiotherapy followed by cisplatin and doxorubicin with or without paclitaxel.

      II. Compare short and long-term toxic effects of these treatment regimens in this patient
      population.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      radiotherapy field (pelvic vs extended field). Within 8 weeks after surgery, patients receive
      tumor volume-directed pelvic radiotherapy with or without paraaortic nodal radiotherapy once
      daily for 5 consecutive days for up to 16 weeks after surgery. Within 8 weeks of completing
      radiotherapy, patients are randomized to 1 of 2 chemotherapy treatment arms.

      Arm I: Patients receive doxorubicin IV over 30 minutes immediately followed by cisplatin IV
      over 1 hour on day 1. Patients also receive filgrastim (G-CSF) subcutaneously (SC) or
      pegfilgrastim on days 2-11.

      Arm II: Patients receive doxorubicin and cisplatin as in arm I, paclitaxel IV over 3 hours on
      day 2, and G-CSF SC or pegfilgrastim on days 3-12. Treatment repeats every 3 weeks for a
      maximum of 6 courses in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 614 patients (307 per treatment arm) will be accrued for this
      study within 5.2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation.</measure>
    <time_frame>study entry up to 5 years post treatment</time_frame>
    <description>Recurrence is defined as discovery of disease not previously present by clinical, radiographic, and/or laboratory means or as a 50% or greater increase in the product of two perpendicular diameters from any documented lesion.
Recurrence-free survival is defined as time in months the patient is alive, recurrence-free starting from the date of randomization.
Intention to treat among eligible participants who receive random treatment allocation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">659</enrollment>
  <condition>Endometrial Adenocarcinoma</condition>
  <condition>Endometrial Adenosquamous Carcinoma</condition>
  <condition>Endometrial Clear Cell Adenocarcinoma</condition>
  <condition>Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation</condition>
  <condition>Endometrial Serous Adenocarcinoma</condition>
  <condition>Stage III Uterine Corpus Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin IV over 30 minutes immediately followed by cisplatin IV over 1 hour on day 1. Patients also receive filgrastim (G-CSF) SC or pegfilgrastim on days 2-11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin and cisplatin as in arm I, paclitaxel IV over 3 hours on day 2, and G-CSF SC or pegfilgrastim on days 3-12. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)</arm_group_label>
    <arm_group_label>Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)</arm_group_label>
    <arm_group_label>Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)</arm_group_label>
    <arm_group_label>Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Nivestim</other_name>
    <other_name>r-metHuG-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)</arm_group_label>
    <arm_group_label>Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>GCSF-SD01</other_name>
    <other_name>Neulasta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>TAX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced endometrial carcinoma with any histology, including:

               -  Clear cell and serous papillary carcinoma

          -  Surgical stage III disease, including:

               -  Positive adnexa

               -  Tumor invading the serosa

               -  Positive pelvic and/or paraaortic nodes

               -  Involvement of bowel mucosa

               -  Intraabdominal metastases

               -  Positive pelvic washings

               -  Vaginal involvement within the radiation port

          -  Must have had prior surgery, including hysterectomy and bilateral
             salpingo-oophorectomy

               -  Tumor maximally debulked to a maximum residual diameter of no greater than 2 cm

               -  Paraaortic lymph node sampling allowed

                    -  If positive, must have negative chest CT scan

          -  No recurrent disease

          -  No parenchymal liver metastases

          -  No disease outside the abdomen

          -  Performance status - GOG 0-2

          -  At least 3 months

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times normal

          -  SGOT/SGPT no greater than 3 times normal

          -  Alkaline phosphatase no greater than 3 times normal

          -  Creatinine no greater than 1.6 mg/dL

          -  LVEF at least 50% within 6 months of study entry

          -  No other prior or concurrent malignancy within the past 5 years except adequately
             treated nonmelanoma skin cancer

          -  No serious comorbid illness that would preclude study participation

          -  No prior chemotherapy

          -  See Disease Characteristics

          -  No prior pelvic or abdominal radiotherapy

          -  No prior radiotherapy for prior malignancy

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Homesley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>May 20, 2014</results_first_submitted>
  <results_first_submitted_qc>May 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2014</results_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Adenocarcinoma, Clear Cell</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients were initially registered and initiated radiation treatment. Following succsessful completion of radiation treatment, participants with no evidence of disease received a random treatment allocation.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>Treatment randomization following RT.
radiation followed by doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 G-CSF 5mcg/kg Days 2-11</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>Treatment randomization following RT:
radiation followed by doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 day 1 paclitaxel 3-Hr 160 mg/m2 day 2 G-CSF 5 mcg/kg days 3-12</description>
        </group>
        <group group_id="P3">
          <title>Radiation (RT) Only</title>
          <description>Tumor volume directed pelvic plus or minus para-aortic irradiation (plus or minus brachytherapy)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="288">total number of participants enrolled, that received random treatment assignment to Arm 1 of study.</participants>
                <participants group_id="P2" count="298">total number of participants enrolled, that received random treatment assignment to Arm 2 of study.</participants>
                <participants group_id="P3" count="73">total number of participants enrolled, that only received radiation treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="223">total number of partipants that completed 6 cycles of chemotherapy.</participants>
                <participants group_id="P2" count="221">total number of partipants that completed 6 cycles of chemotherapy.</participants>
                <participants group_id="P3" count="0">total number of partipants that completed 6 cycles of chemotherapy.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused further treatment</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total number of eligible participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Treatment randomization following RT.
radiation followed by doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 G-CSF 5mcg/kg Days 2-11</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>Treatment randomization following RT:
radiation followed by doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 day 1 paclitaxel 3-Hr 160 mg/m2 day 2 G-CSF 5 mcg/kg days 3-12</description>
        </group>
        <group group_id="B3">
          <title>Radiation (RT) Only</title>
          <description>Tumor volume directed pelvic plus or minus para-aortic irradiation (plus or minus brachytherapy)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="270"/>
            <count group_id="B2" value="282"/>
            <count group_id="B3" value="64"/>
            <count group_id="B4" value="616"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="11.1"/>
                    <measurement group_id="B2" value="58.8" spread="9.5"/>
                    <measurement group_id="B3" value="63.9" spread="10.7"/>
                    <measurement group_id="B4" value="59.3" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="282"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation.</title>
        <description>Recurrence is defined as discovery of disease not previously present by clinical, radiographic, and/or laboratory means or as a 50% or greater increase in the product of two perpendicular diameters from any documented lesion.
Recurrence-free survival is defined as time in months the patient is alive, recurrence-free starting from the date of randomization.
Intention to treat among eligible participants who receive random treatment allocation.</description>
        <time_frame>study entry up to 5 years post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Treatment randomization following RT.
doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 G-CSF 5mcg/kg Days 2-11</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Treatment randomization following RT:
doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 day 1 paclitaxel 3-Hr 160 mg/m2 day 2 G-CSF 5 mcg/kg days 3-12</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation.</title>
          <description>Recurrence is defined as discovery of disease not previously present by clinical, radiographic, and/or laboratory means or as a 50% or greater increase in the product of two perpendicular diameters from any documented lesion.
Recurrence-free survival is defined as time in months the patient is alive, recurrence-free starting from the date of randomization.
Intention to treat among eligible participants who receive random treatment allocation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alive, Recurrence-Free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence or Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary outcome is measured as a treatment hazard ratio stratified by stage and assuming proportional hazards.
Recurrence-free survival hazard ratio: Arm 2 is relative to Arm 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The frequencies of any serious adverse event or other adverse events by category or specific term occurring during chemotherapy treatment and up to 30 days after stopping the study treatment are reported.</time_frame>
      <desc>Serious Adverse Events(SAE) are reported separately. Due to the methods in which AEs were collected &amp;/or stored, it isn't possible to report Other AEs separate from SAEs. That table is a combined set of SAEs &amp; non-serious AEs. Other AEs are acute, grade 2 or worse AEs that occured during chemotherapy treatmentand don't include late AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Treatment randomization following RT.
doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 G-CSF 5mcg/kg Days 2-11</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Treatment randomization following RT:
doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 day 1 paclitaxel 3-Hr 160 mg/m2 day 2 G-CSF 5 mcg/kg days 3-12</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/Granulocytes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory or Cardia, Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Vasovagal Episode</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Cardia-Ischemia/Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Diarrhea (without Colostomy)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Abdominal Pain or Cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pain, Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Infection Documented with Grade 3/4 Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Infection without Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia-Fuo Infection Not Documented</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis (Avascular Necrosis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cns Cerebrovascular Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Neuropathy-Sensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound-Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="278" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="236" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Other Hematologic</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Lymphatics</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac left ventricular function</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Other Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Other Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Without Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Other Infection/Fever</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>2nd Primary</sub_title>
                <description>2nd primary is not necessarily secondary malignancy and may have been reported any time after randomization including the follow-up period.</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Sensory Neurologic</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Other Neurologic</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary/Renal</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hepatic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Other Dermatologic</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela M. Kuras, Associate Director of Data Management</name_or_title>
      <organization>NRG Oncology Statistics and Data Management Center - Buffalo</organization>
      <phone>716-845-7733</phone>
      <email>kurasa@nrgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

